| Title: | Urine as a biological modality for colorectal cancer detection |
| Author(s): | Chandrapalan S; Arasaradnam RP; |
| Address: | "Department of Gastroenterology, University Hospital of Coventry and Warwickshire, Coventry, UK. Warwick Medical School, University of Warwick, Coventry, UK. Health, Biological & Experimental Sciences, University of Coventry, Coventry, UK. School of Health Sciences, University of Leicester, Leicester, UK" |
| DOI: | 10.1080/14737159.2020.1738928 |
| ISSN/ISBN: | 1744-8352 (Electronic) 1473-7159 (Linking) |
| Abstract: | "Introduction: The increasing incidence of colorectal cancer (CRC) in young adults warrants early and preferably noninvasive diagnostic modalities. Although the current stool-based assays have had good performance indicators for CRC detection, the overall poor uptake remains a challenging issue. However, alternative blood and urine markers are emerging.Areas covered: This paper discusses the various urinary biomarkers available for the detection of CRC. The more commonly encountered drawbacks are the small number of studies and the size of the study population. We discuss the role of microRNA and ProstaglandinE2 in CRC detection. The emergence of new, low-cost technologies, specifically in the detection of volatile organic compounds (VOCs), presents a promising future. We postulate possible mechanisms for the origin of these VOCs in urine and their role in carcinogenesis.Expert opinion: Urinary biomarkers provide an alternative option to the stool-based screening tests. MicroRNA and ProstaglandinE2 have shown utility in CRC detection. Evidence so far suggests that VOCs could also be a potential biomarker for the detection of CRC. In addition to its interaction within the colon lumen, this altered 'VOC signature' might also play a role in carcinogenesis. Low-cost technology may enable such diagnostic methods to be utilized at the point of care" |
| Keywords: | "Biomarkers, Tumor/*urine Colorectal Neoplasms/*diagnosis/epidemiology/*urine Dinoprostone/urine Early Detection of Cancer/economics/methods/standards Humans Liquid Biopsy/methods Mass Screening/methods MicroRNAs/urine Prognosis Sensitivity and Specificity;" |
| Notes: | "MedlineChandrapalan, Subashini Arasaradnam, Ramesh P eng England 2020/03/05 Expert Rev Mol Diagn. 2020 May; 20(5):489-496. doi: 10.1080/14737159.2020.1738928. Epub 2020 Mar 11" |
